Edition:
United Kingdom

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

109.00EUR
12:26pm BST
Change (% chg)

€0.90 (+0.83%)
Prev Close
€108.10
Open
€108.60
Day's High
€109.50
Day's Low
€108.50
Volume
39,893
Avg. Vol
117,692
52-wk High
€109.50
52-wk Low
€68.60

Latest Key Developments (Source: Significant Developments)

DiaSorin H1 Net Profit Up At EUR 84.0 Mln
Wednesday, 31 Jul 2019 

July 31 (Reuters) - DiaSorin SpA ::H1 REVENUE EUR 350.3 MILLION VERSUS EUR 331.2 MILLION YEAR AGO.H1 NET PROFIT EUR 84.0 MILLION VERSUS EUR 80.9 MILLION YEAR AGO.2019 GUIDANCE AT CER CONFIRMED, SEES REVENUE GROWTH BETWEEN 5.0% AND 8.0%.2019 GUIDANCE AT CER CONFIRMED: INCIDENCE ON GROUP REVENUES COMPARABLE TO 2018 EBITDA MARGIN RESULT.  Full Article

Diasorin And Qiagen Expand Collaboration For QuantiFERON Technology
Wednesday, 5 Jun 2019 

June 5 (Reuters) - DiaSorin SpA ::SAYS DIASORIN AND QIAGEN ANNOUNCE EXPANSION OF COLLABORATION FOR QUANTIFERON TECHNOLOGY.NEW TEST BASED ON QUANTIFERON TECHNOLOGY FOR DIAGNOSIS OF LYME DISEASE WILL BE USED ON LIAISON PLATFORMS.  Full Article

Diasorin Launches Elastasi-1 Test For Diagnosis Of Chronic Exocrine Pancreatitis On Liaison Xl
Monday, 6 May 2019 

May 6 (Reuters) - DiaSorin SpA ::LAUNCHES ELASTASI-1 TEST FOR DIAGNOSIS OF CHRONIC EXOCRINE PANCREATITIS ON LIAISON XL.  Full Article

DiaSorin Launches Molecular Test Simplexa Bordetella Direct In U.S. Market
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - DiaSorin SpA ::LAUNCHES MOLECULAR TEST SIMPLEXA BORDETELLA DIRECT IN U.S. MARKET.  Full Article

DiaSorin Launches Molecular Test To Detect Group B Strep On U.S. Market
Monday, 19 Nov 2018 

Nov 19 (Reuters) - DiaSorin SpA ::LAUNCHES MOLECULAR TEST TO DETECT GROUP B STREP ON U.S. MARKET.  Full Article

Diasorin sees potential negative impact from Iran, contracts delay
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - DiaSorin CEO Carlo Rosa says::2018 GUIDANCE COULD BE NEGATIVELY IMPACTED BY IRAN AND DELAY IN CONTRACTS.  Full Article

Diasorin CEO expects vitamin D volumes in US to fall 20 pct over next 12 mths
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - DiaSorin CEO Carlo Rosa says::EXPECTS 20 PERCENT FALL IN VITAMIN D VOLUMES IN THE US MARKET OVER NEXT 12 MONTHS.  Full Article

DiaSorin Q3 Net Profit Up At EUR 35.9 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - DiaSorin SpA ::Q3 NET PROFIT EUR 35.9 MILLION VERSUS EUR 29.3 MILLION YEAR AGO.Q3 REVENUE EUR 162.8 MILLION VERSUS EUR 149.4 MILLION YEAR AGO.  Full Article

Diasorin SpA Receives CE Marking For Its New Simplexa VZV Direct assay
Friday, 12 Oct 2018 

Oct 12 (Reuters) - DiaSorin SpA ::ANNOUNCED TO HAVE RECEIVED CE MARKING FOR ITS NEW SIMPLEXA VZV DIRECT ASSAY.  Full Article

Diasorin Launches New Liaison Quantiferon-TB Gold Plus In Partnership With Qiagen
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Diasorin Spa ::LAUNCHES NEW LIAISON QUANTIFERON-TB GOLD PLUS ASSAY AS AN AID FOR LATENT TUBERCULOSIS DETECTION IN PARTNERSHIP WITH QIAGEN.SAYS TEST WAS DEVELOPED IN A PARTNERSHIP BETWEEN DIASORIN AND QIAGEN.SAYS TEST WILL BE LAUNCHED IN U.S. BY 2019 AND IN CHINA BY 2020.  Full Article

Italy - Factors to watch on July 31

The following factors could affect Italian markets on Wednesday.